What did the FDA’s new GLP-1 warning say about vision loss?
The FDA now requires every GLP-1 medication to list a potential increased risk of NAION in the Warnings and Precautions section of its label. The agency announced the change in a Drug Safety Communication on November 9, 2026.
GLP-1 receptor agonists mimic a natural hormone that helps control blood sugar and appetite. Doctors prescribe them for type 2 diabetes and weight management. The warning covers the whole class: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda, Xultophy), dulaglutide (Trulicity), lixisenatide with insulin glargine (Soliqua), generic exenatide and orforglipron (Foundayo).
What is NAION, and what does it feel like?
NAION (non-arteritic anterior ischemic optic neuropathy) is a rare condition in which poor blood flow damages the optic nerve, causing sudden, painless vision loss in one eye. The optic nerve carries signals from the eye to the brain, and “ischemic” means the nerve is not getting enough blood. The FDA notes that patients may first notice the vision loss when they wake up.
NAION is not limited to people taking GLP-1 drugs. The FDA cites a background rate of 2.3 to 10.2 cases per 100,000 adults over age 50 each year. According to the AAO, ischemic optic neuropathy is more likely in people 50 and older and in people with high blood pressure, high cholesterol, diabetes, sleep apnea or heart disease.
The AAO’s EyeWiki adds that most people who develop NAION have a small, crowded optic nerve head, a feature eye doctors look for when they examine the eye.
How common is NAION on GLP-1 drugs like Ozempic, and do they cause it?
NAION is rare in people taking GLP-1 drugs, the added risk the FDA found is small, and no one has proven the drugs cause it. In the FDA’s analysis of 126 clinical trials, NAION occurred 6.4 times per 100,000 person-years on a GLP-1 drug and 3.8 times on a placebo or a different diabetes drug. A person-year is one person taking a medication for one year.
In real-world insurance data from the FDA’s Sentinel system, adults with type 2 diabetes who started a GLP-1 drug had a 43% higher risk of NAION than those who started a DPP-4 inhibitor, another diabetes pill. Compared with an SGLT-2 inhibitor, a third type of diabetes drug, the difference was not statistically significant. In June 2025, the EMA’s safety committee classified NAION as a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 people taking it.
The AAO states that “it has not been established that these medications cause NAION.” A review of animal studies found no mechanism. NAION’s risk factors also overlap with the conditions GLP-1 drugs treat, including diabetes, high blood pressure, sleep apnea, smoking, anemia and kidney disease, according to the FDA’s review as summarized by Pharmacy Times.
What should you do if you experience sudden vision loss while taking a GLP-1?
Call your eye doctor or health care professional right away. The FDA advises patients to report sudden, painless vision loss in one eye right away. In a November 11, 2026 statement, the AAO said patients “should not stop a GLP-1 RA medication on their own because of the FDA announcement.”
The FDA tells prescribers to refer suspected NAION promptly to an ophthalmologist, a medical doctor who specializes in eye disease and surgery. If NAION is confirmed, the FDA advises prescribers to “consider discontinuing” the GLP-1 unless the benefits “clearly outweigh the risk.” That decision belongs to you and your prescriber, with input from your eye doctor.
People who have already had NAION have a higher risk of it happening again, according to the FDA. The AAO advises them to discuss the potential risk to the other eye with their physicians.
Do you need an eye exam before or while taking a GLP-1 drug in Omaha?
The AAO does not specifically recommend eye exams only to check NAION risk before starting a GLP-1, but people with diabetes should keep their regular diabetic eye exams. The AAO’s November 2026 guidance says “routine eye examinations solely to assess NAION risk” are not recommended based on current evidence.
GLP-1 drugs are often prescribed for type 2 diabetes, which can damage blood vessels in the retina, the light-sensing layer at the back of the eye. This damage is called diabetic retinopathy. The Ozempic prescribing information reports that in a 2-year trial, diabetic retinopathy complications occurred in 3.0% of people taking Ozempic and 1.8% of people taking a placebo. The label adds that rapid improvement in blood sugar control has been linked to a temporary worsening of diabetic retinopathy.
Key takeaways
- The FDA added a potential NAION risk warning to every GLP-1 drug label on November 9, 2026.
- NAION is rare, the added risk is small, and no one has proven GLP-1 drugs cause it.
- Sudden vision loss in one eye needs a call to your eye doctor right away.
- Keep taking your GLP-1 until you talk with your prescriber, and keep diabetic eye exams on schedule.
Frequently asked questions about GLP-1 drugs and NAION
Does NAION cause blindness?
NAION usually causes partial vision loss in one eye, not total blindness. According to the AAO’s EyeWiki, losing all light perception from NAION is exceptionally rare, and the most common pattern is loss of the upper or lower part of the visual field, most often the lower part. In long-term follow-up, about half of NAION patients had 20/30 vision or better in the affected eye, and nearly one-quarter had 20/200 or worse.
Does vision come back after NAION?
The AAO states that vision loss from ischemic optic neuropathy is usually permanent, though some patients improve. According to the AAO’s EyeWiki, vision typically stabilizes within about two months, and studies report that 13% to 43% of NAION patients regain at least three lines on an eye chart.
How do I report vision problems from a GLP-1 drug?
Tell your prescriber and your eye doctor first. Patients and doctors can also report side effects to the FDA’s MedWatch program online or by calling 1-800-332-1088.
Where can you get a medical eye exam in Omaha?
ilumin Eye Care Center’s board-certified ophthalmologists see patients at 16820 Frances Street, Suite 100, in Omaha. The practice provides diabetic eye care, glaucoma treatment, cataract surgery and macular degeneration therapy.
Schedule an eye exam at ilumin
If you are due for an eye exam or want to talk through a change in your vision, schedule an eye exam online or call ilumin Eye Care Center at 402-933-6600.